# Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation

> **NCT06862726** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **Les Laboratoires des Médicaments Stériles** · enrollment: 120 (estimated)

## Conditions studied

- Non Valvular Atrial Fibrillation

## Interventions

- **DRUG:** Anti Xa dosage
- **DRUG:** Dosage of PT-INR

## Key facts

- **NCT ID:** NCT06862726
- **Lead sponsor:** Les Laboratoires des Médicaments Stériles
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-12-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06862726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06862726, "Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06862726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*